R(+)-8-OH-DPAT, a serotonin(1A) receptor agonist, potentiated S(-)- sulpiride-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens but not striatum

Journal of Pharmacology and Experimental Therapeutics

Volumn 291, Issue 3, 1999, Pages 1227-1232

  Ichikawa, Junji ^a,b   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 DIPROPYLAMINO 8 HYDROXYTETRALIN; DOPAMINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; SULPIRIDE;

ANIMAL EXPERIMENT; ARTICLE; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOSE RESPONSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; MALE; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; DOPAMINE; DOPAMINE ANTAGONISTS; DRUG SYNERGISM; EXTRACELLULAR SPACE; MALE; MICRODIALYSIS; NEOSTRIATUM; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; STIMULATION, CHEMICAL; SULPIRIDE;

EID: 0032732960     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. 1A agonist 8-OH-DPAT in the rat. Pharmacol Toxicol 64:3-5.
2. Andersson JL, Nomikos GG, Marcus M, Hertel P, Mathé JM and Svensson TH (1995) Ritanserin potentiates the stimulatory effects of raclopride on neuronal activity and dopamine release selectively in the mesolimbic dopaminergic system. Naunyn-Schmiedeberg's Arch Pharmacol 352:374-385.
3. 1A receptor selective ligands, (R)-8-OH-DPAT and (S)-UH-301, differentially affect the activity of midbrain dopamine neurons. Naunyn-Schmiedeberg's Arch Pharmacol 347:353-362.
4. 3 dopamine receptor, in rat brain: A receptor binding and quantitative autoradiographic study. Neuropsychopharmacology 18:305-316.
5. Chen N-H and Reith MEA (1995) Monoamine interactions measured by microdialysis in the ventral tegmental area of rats treated systemically with (±)-8-hydroxy-2-(di-n-propylamino)tetralin. J Neurochem 64:1585-1597.
6. Davis KL, Kahn RS, Grant K and Davidson M (1991) Dopamine in schizophrenia: A review and reconceptualization. Am J Psychiatry 148:1474-1486.
7. 3 receptors. J Neurosci 18:6528-6538.
8. 3 receptor agonist cis-8-OH-PBZI. Eur J Pharmacol 342:153-161.
9. 1A receptor antagonist, WAY-100635. Eur J Pharmacol 281:81-88.
10. 3 (auto)receptors inhibit dopamine release in the frontal cortex of freely moving rate in vivo. J Neurochem 68:2209-2212.
11. Guatafsson B and Christensson E (1990) Amperozide - A new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behaviour. Pharmacol Toxicol 66:12-17.
12. Hoffman DC and Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120:128-133.
13. 1A agonist, inhibits amphetamine-induced dopamine release in rat striatum and nucleus accumbens. Eur J Pharmacol 287:179-184
14. 1A receptors on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens. Brain Res, in press.
15. 2A antagonist, potentiates the ability of R(+)-8-OH-DPAT to increase extracellular dopamine (DA-ext) levels in rat medial prefrontal cortex (mPFC). Soc Neurosci Abstr 25:488.9.
16. 1A receptor antagonist, to rat brain. J Neurochem 64:2716-2726.
17. Kohl RR, Katner JS, Chernet E and McBride WJ (1998) Ethanol and negative feedback regulation of mesolimbic dopamine release in rats. Psychopharmacology 139:79-85.
18. 1A receptor agonist, in rat medial prefrontal cortex. Brain Res 743:357-361.
19. Kuroki T, Meltzer HY and Ichikawa J (1999) Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288:774-781.
20. 1A receptor agonist, potentiated S(-)-sulpiride (SUL)-induced DA release in rat medial prefrontal cortex (mPFC). Soc Neurosci Abstr 23:401.
21. 1C/2 antagonists as therapeutic agents. Drug News Perspectives 5:397-406.
22. 1A agonist properties: I. Receptorial and neurochemical profile in comparison with clozapine and haloperidol. J Pharmacol Exp Ther 286:1341-1355.
23. 1A receptor antagonist (S)-UH-301 decreases dopamine release in the rat nucleus accumbens and striatum. J Neural Transm 103:541-554.
24. Paxinos G and Watson C (1986) The Rat Brain in Stereotaxic Coordinates, Academic Press, New York.
25. 1A receptor in the rat brain: Correlation with receptor binding. J Neurosci 12:440-453.
26. 1A agonist ±8-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine. Synapse (NY) 18:218-224.
27. 3 receptor antagonist, (+)-S 14297. Eur J Pharmacol 265:175-177.
28. 0 proteins in dorsal raphe nucleus. Eur J Pharmacol 265:103-106.
29. 3 receptor coexistence. Brain Res Rev 26:236-242.
30. Seeger TF, Seymour PA, Schmidt AW, Zorn SH, Schulz DW, Lebel LA, McLean S, Guanowsky V, Howard HR, Lowe JA and Heym J (1995) Ziprasidone (CP-88,059): A new antipsychotic with combined dopamine and serotonin receptor antagonist activity. J Pharmacol Exp Ther 275:101-113.
31. Seeman P and Van Tol HHM (1994) Dopamine receptor pharmacology. Trend Pharmacol Sci 15:264-269.
32. 3) as a target for neuroleptics. Nature (Lond) 347:146-151.
33. Tanda G, Caroni E, Frau R and Di Chiara G (1994) Increase of extracellular dopamine in the prefrontal cortex: A trait of drugs with antidepressant potential? Psychopharmacology 115:285-288.
34. 2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology 98:45-50.
35. Wadenberg ML (1996) Serotonergic mechanisms in neuroleptic-induced catalepsy in the rat. Neurosci Biobehav Rev 20:325-339.
36. Wadenberg ML and Ahlenius S (1991) Antipsychotic-like profile of combined treatment with raclopride and 8-OH-DPAT in the rat: Enhancement of antipsychotic-like effects without catalepsy. J Neural Transm 83:43-53.
37. 2A receptor antagonist MDL 100,907. Biol Psychiatry 44:508-515.
38. 2 receptor antagonist, raclopride, by the additional treatment with the 5-HT2 receptor blocking agent, ritanserin, in the rat. Eur J Neuropsychopharmacol 6:305-310.
39. Willner P (1997) The mesolimbic dopamine system as a target for rapid antidepressant action. Int Clin Psychopharmacol 12:S7-S14.
40. Yoshimoto K and McBride WJ (1992) Regulation of nucleus accumbens dopamine release by the dorsal raphe nucleus in the rat. Neurochem Res 7:401-407.
41. Zifa E and Fillion G (1992) 5-Hydroxytryptamine receptors. Pharmacol Rev 44:401-449.